Adagrasib D5 | CAS 2641914-61-4 - Request Quote
Adagrasib D5
| SZ CAT No: | SZ-A158D01 |
| CAS No | 2641914-61-4 |
| Mol.F. | C32H30D5ClFN7O2 |
| Mol.Wt. | 609.2 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Adagrasib D5 is chemically 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-(methyl-d3)pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl-8,8-d2)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile. Adagrasib D5 is supplied with detailed characterization data compliant with regulatory guideline. Adagrasib D5 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Adagrasib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 2641914-61-4
Purchase 2641914-61-4
Order 2641914-61-4
Enquire 2641914-61-4
price of 2641914-61-4
2641914-61-4 Supplier
2641914-61-4 Manufacturer
2641914-61-4 Exporter
buy high quality Adagrasib D5
Purchase Adagrasib D5
Adagrasib D5 suppliers
Adagrasib D5 manufacturers
Adagrasib D5 price
Order Adagrasib D5
Enquire Adagrasib D5
Adagrasib D5 cost
Adagrasib D5 Supplier
Adagrasib D5 Distributor
Adagrasib D5 for Method Validation
Adagrasib Reference Standard
Adagrasib D5 for ANDA Filing
Adagrasib D5 for Forced Degradation Studies
Adagrasib D5 Identification Standards
Adagrasib D5 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


